Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo

Interleukin 7 (IL-7) protein has been reported to be important in the devel opment of cytotoxic-T-lymphocyte (CTL) responses. However, other studies al so support a partial Th2 phenotype for this cytokine. In an effort to clari fy this unusual conflict, we compared IL-7 along vith IL-12 (Th1 central) a nd IL-IO (Th2 control) for its ability to induce antigen (Ag)-specific CTL and Th1- versus Th2-type immune responses using a well established DNA vacc ine model. In particular, IL-7 codelivery showed a significant increase in immunoglobulin G1 (IgG1) levels compared to IgG2a levels. IL-7 coinjection also decreased production of Th1-type cytokine IL-2, gamma interferon, and the chemokine RANTES but increased production of the Th2-type cytokine IL-1 0 and the similarly biased chemokine MCP-1. In herpes simplex virus (HSV) c hallenge studies, IL-7 coinjection decreased the survival rate after lethal HSV type 2 (HSV-2) challenge compared with go plasmid vaccine alone in a m anner similar to IL-10 coinjection, whereas IL-12 coinjection enhanced the protection, further supporting that IL-7 drives immune responses to the Th2 type, resulting in reduced protection against HSV-2 challenge. Moreover, c oinjection with human immunodeficiency virus type 1 env and gag/pol genes p lus IL-12 or IL-7 cDNA enhanced Ag-specific CTLs, while coinjection with IL -10 cDNA failed to influence CTL induction. Thus, IL-7 could drive Ag-speci fic Th2-type cellular responses and/or CTL responses. These results support that CTLs could be induced by IL-7 in a Th2-type cytokine and chemokine en vironment in vivo. This property of IL 7 allows for an alternative pathway for CTL development which has important implications for host-pathogen resp onses.